Expanding Horizons Beyond Human Healthcare
On June 30, 2025, Fredun Pharmaceuticals Limited took a major leap in diversifying its healthcare offerings by formally entering the pet care segment. Through its wholly owned subsidiary, Fredun Retail Private Limited (FRPL), the company acquired a controlling stake in One Pet Stop Private Limited, a prominent name in pet grooming and wellness services.
Tapping into India’s Fast-Growing Pet Care Market
India’s pet care industry is witnessing exponential growth, expected to reach USD 1.87 billion (INR 149.6 billion) by 2029 with a CAGR of 17.1%. The rising number of nuclear families and urban lifestyles is driving a surge in pet ownership, especially in metros. By acquiring One Pet Stop, Fredun strategically positions itself within this booming segment, aligning with its goal of becoming a holistic provider of both human and animal wellness.
Access to a Loyal Consumer Base and Tech-Driven Services
One Pet Stop brings with it a robust customer base of over 4,000 recurring pet owners. The company is known for its tech-enabled, doorstep grooming services delivered through temperature-controlled vans and a user-friendly mobile app. Services include grooming by certified professionals, health reminders, and real-time updates—all contributing to long-term customer engagement and trust.
Strategic Synergies with Fredun’s Existing Portfolio
This acquisition creates strong alignment with Fredun’s Freossi brand, which offers premium pet grooming products. With One Pet Stop’s B2C service model and Fredun’s manufacturing and distribution infrastructure, the company plans to expand aggressively in high-consumption zones, including the Mumbai Metropolitan Region (MMRDA) and other urban areas.
Commitment to Quality and Innovation
One Pet Stop’s partnerships with brands like Dyson and Tropiclean reinforce its commitment to superior hygiene and care. With Fredun’s backing, the company aims to scale operations while maintaining industry-leading service standards.
Strong Financial Backbone and Future Outlook
Fredun Pharmaceuticals reported FY25 revenues of ₹456 crore, EBITDA of ₹55 crore, and PAT of ₹21 crore. With a solid financial base, this acquisition marks a natural progression in Fredun’s expansion journey.Managing Director Fredun Medhora emphasized, “This acquisition is a transformative step toward redefining pet wellness in India and aligns with our broader mission of accessible, innovative healthcare across all life forms.”With this move, Fredun Pharmaceuticals is well on its way to becoming a key player in the pet care ecosystem.
Did you find this article interesting?
Stay connected with our blog for more insights and updates. We’d love to hear your thoughts, questions, or feedback in the comments below!
Cyient Semiconductor and MIPS Partner for Next-Gen Custom Silicon Solutions
Regular insider buying reported in these shares. Does it give any signal to the investors ?
